Novo Nordisk A-S

Yahoo Finance • 21 hours ago

Fractyl Health says procedure can maintain weight loss after stopping GLP-1

[Successful diet. Young female in oversized jeans demonstrating results of her slimming] Prostock-Studio * Fractyl Health (GUTS [https://seekingalpha.com/symbol/GUTS]) said that data from an open-label study of its Revita outpatient end... Full story

Yahoo Finance • 22 hours ago

Novo's $1 Billion Obesity Bet Just Took a Shocking Turn--And It Starts With 8-Year-Olds

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) is moving into its next chapter with CagriSema, and the pivot could be more ambitious than many investors expected. Despite recent adult studies that delivered lower-than-a... Full story

Yahoo Finance • 22 hours ago

European Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were higher late Tuesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • yesterday

Lockheed Martin lands $52 million U.S. Army contract for rocket systems

[Lockheed Martin Canada Mission Systems and Training in Ottawa on August 8, 2020] JHVEPhoto/iStock Editorial via Getty Images * Lockheed Martin (LMT [https://seekingalpha.com/symbol/LMT]) was awarded a $52 million cost-plus-fixed-fee, f... Full story

Yahoo Finance • 2 days ago

Are GLP-1s The New Performance-Enhancing Drug For Careers?

Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the ques... Full story

Yahoo Finance • 2 days ago

European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension

Company Logo Key market opportunities include. Companies like Novo Nordisk, Regeneron, AstraZeneca, and Vertex are leading innovation, presenting new avenues for treatment in metabolic and cardiovascular conditions. Dublin, Dec. 01, 2025... Full story

Yahoo Finance • 2 days ago

Lilly Cuts Prices for Cash Buyers of Weight-Loss Drug Zepbound

Eli Lilly is cutting prices again for those who pay cash for introductory doses of the weight-loss drug Zepbound. The lowest dose vial will cost $299 a month, that would be a saving of about $50. It's part of the price war with rival Novo... Full story

Yahoo Finance • 2 days ago

UK to pay 25% more for new drugs under deal with US

[Pile of different colourful pills placed next to 20 British pound banknotes.] Oleksandr Siedov An agreement in principle reached between UK and US trade negotiators will have the latter's National Health Service pay 25% higher list price... Full story

Yahoo Finance • 2 days ago

Omeros, Novo Nordisk close up to $2.1B deal for phase 2 asset zaltenibart

[New Nordisk] hapabapa * Omeros (OMER [https://seekingalpha.com/symbol/OMER]) and Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) have closed a deal worth up to $2.1B for the former's phase 2 asset zaltenibart, in development f... Full story

Yahoo Finance • 2 days ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

SEATTLE, December 01, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Za... Full story

Yahoo Finance • 2 days ago

Novo Nordisk's Latest Clinical Result Is Sending the Stock Plunging. Here's What Investors Need to Know.

Key Points Semaglutide failed to demonstrate slowed Alzheimer’s progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ~45% YTD amid pricing pressur... Full story

Yahoo Finance • 2 days ago

Roche shares hit milestone with 19% November surge on breast cancer and promising MS drug trials

[Scientist analyze biochemical samples in advanced scientific laboratory. Medical professional use microscope look microbiological developmental of viral. Biotechnology research in science lab.] Shares of Swiss pharmaceutical giant Roche... Full story

Yahoo Finance • 3 days ago

Notable healthcare headlines for the week: Sanofi, Eli Lilly, and Novo Nordisk in focus

U.S. stocks rallied over the trading week, shortened by the Thanksgiving holiday and a reduced trading session on Friday. The S&P 500 was up around 4% during the week, while the Dow rose a similar amount and the tech-focused Nasdaq Compos... Full story

Yahoo Finance • 5 days ago

Why Eli Lilly's 'market-cap explosion' might be 'misplaced'

Mizuho Americas healthcare equity strategist, Jared Holz, joins Market Catalysts host Julie Hyman to discuss Eli Lilly's (LLY) stock action, how the GLP-1 market has played a part, and whether Eli Lilly will see serious competition in the... Full story

Yahoo Finance • 5 days ago

Novo Nordisk submits FDA application for higher dose Wegovy

[Semiglutide Injection pen-once a week treatment] Scharvik/iStock via Getty Images * Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) has filed an sNDA with the US FDA for approval of a 7.2 mg dose of its weight loss therapy Weg... Full story

Yahoo Finance • 5 days ago

Novo Nordisk (CPSE:NOVO B): Exploring Valuation After Recent Share Price Pullback

Novo Nordisk (CPSE:NOVO B) shares have seen a modest decline over the past month, reflecting shifts in investor sentiment and market conditions. Many are now watching how recent developments could impact the company's longer-term outlook.... Full story

Yahoo Finance • 6 days ago

Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?

Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized as the market leader in the GLP-1 spac... Full story

Yahoo Finance • 6 days ago

Prediction: This Undervalued Stock Could Compete With Novo Nordisk by 2029

Key Points Viking Therapeutics could enter the weight loss market by 2029. The company's leading candidate looks very promising. The biotech is somewhat risky, but it also offers attractive upside potential. 10 stocks we like better than... Full story

Yahoo Finance • 6 days ago

What Developments Are Shaping the Evolving Narrative for Novo Nordisk?

Analysts have recently revised their consensus price target for Novo Nordisk stock, reducing it from DKK 431.99 to DKK 400.24. This adjustment reflects both optimism about the company’s strategic strengths and caution regarding its near-te... Full story

Yahoo Finance • 7 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index easing 0.1% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story